All Type of News
Boryung seeking sales of 100 billion won with new antihypertensive
Boryung Pharmaceutical Co., one of Korea's largest pharmaceutical companies, said on September 9 that its newly approved fimasartan, a new angiotensin II receptor blocker, is expected to generate 100 billion won ($87 ...
KFDA suggests strict sealing process
The Korea Food and Drug Administration suggested that some of multinational drug manufacturers observe the sealing regulation of drugs before their release to pharmacies.
The Korean Pharmaceutical Association said ...
Two wholesalers to set up holding firm
Two local wholesalers in Seoul – SongAm Pharm and Kiyoung Pharm – said on September 9 that they plan to establish a holding company in an effort to streamline their corporate structure within this year.
A working-l...
Korea eying artificial joint markets
Influenced by the rising demand for artificial joints at home and abroad, the Korea Food and Drug Administration is making all-out to support the earliest launching of medical devices which are/will be produced by Kor...
Fimasartan, new hypertensive agent, receives marketing approval in Korea
Boryung Pharmaceutical Co., one of Korea's largest pharmaceutical companies, announced on September 9 that they received marketing approval from the Korean Food and Drug Administration (KFDA) for fimasartan, their new...
Foreign investors keen on pharmaceutical shares
Pharmaceutical shares are emerging as the new leading themes of the stock market this year as foreign investors has recently been at the forefront of purchasing pharmaceutical shares.
The U.S. based FID Low Priced ...
Medical bills for patients with spine disease will go down
The costs that individuals will have to shoulder for treatment of spine and joint diseases will go down from October thanks to the government’s plan to restructure the national health insurance scheme, the Ministry fo...
4 drug makers spend over 10 billion won on advertisement
Details of Korean company spending on advertisement revealed recently show that four pharmaceutical firms, such as Ildong Pharm, Dongkook Pharm, Myungin Pharm and Dong-A Pharm, spent more than 10 billion won in the fi...
Hanall to conduct phase 2 trial for protein therapeutic in US
Hanall BioPharma says it has filed its phase 2 application for its lead protein product, Hanferon (interferon alpha), to the U.S. Food and Drug Administration.
If approved, the company will conduct phase 2 trial in...
Drugmakers keen on expanded coverage of DMF system
The Korea Food and Drug Administration is considering providing assistance to industry, in particular Active Pharmaceutical Ingredient (API) manufacturers, on the requirements of drug substance as the drug agency inte...
